gland pharma glp-1 manufacturing Q4 net profit slips 3% as US sales moderate; focus shifts to complex injectables, CDMO growth Complex Pharma: Waiting by the

Seghal added that the findings are not definitive: "We can't say that GLP-1s are actually causing these symptoms." Copyright 2026 Nexstar Media, Inc

Favor evidence over trends

Our quality assurance process ensures consistent peptide integrity and purity across all shipments to Canadian research institutions

Baker J

Without randomized, long-term studies on the use of GLP-1 RAs in a large sample size of HS patients with a wide range of ages, comorbidities, risk factors, and sexes and without any confounding factors, it is difficult to conclusively determine whether GLP-1 RAs are a definitive treatment for HS

What was BPC-157 used for